| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Medicine, University of Cambridge Clinical School, Cambridge, United Kingdom
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To address the relationship between CD28-CD8+
T cells and Ag-specific T cell memory, we studied human virus-specific
CD8+ CTL, which play an important role in the control of
human persistent virus infections (9). CD8+ CTL recognize
viral peptide Ag presented by MHC class I molecules on the surface of
virus-infected cells via the TCR 
ß heterodimer that is generated
during thymic development by rearrangement of variable (V), diversity
(D), and joining (J) gene segments. Additional TCR diversity is
generated by imperfect joining of these segments, exonucleotide
nibbling at the joins, and addition of nongermline-encoded N-region
nucleotides. The regions spanning the V-(D)-J joins constitute the
hypervariable CDR3 regions that interact with the middle of the bound
peptide and account for approximately 50% of TCR’s interaction with
peptide (10).
Following primary infection with the betaherpesvirus HCMV,3 the virus persists lifelong in a latent state in cells of the myeloid lineage under the control of the immune system (11). In immunocompromised individuals, including patients with advanced HIV infection, HCMV reactivation often causes serious disease (12). We previously studied the HCMV-specific memory CTL response of healthy, long term HCMV carriers and quantified high frequencies of MHC-restricted HCMV-specific CTL precursors (CTLp) in peripheral blood, a large proportion of which recognized the viral tegument protein pp65. In most donors, the CTL response to this protein was highly focused on a small number of epitopes within pp65 (13). We analyzed the clonal composition of memory CTL in HCMV carriers by generating multiple independent peptide-specific CTL clones and sequencing the hypervariable VDJ region of the TCR ß-chain of each clone. We found that the strong memory CTL response against a given viral peptide contains individual CTL clones that had undergone extensive expansion in vivo (14). In HIV infection there is a vigorous HIV-specific CD8+ CTL response that is temporally associated with partial control of viral replication (15, 16, 17). During asymptomatic HIV infection, a high frequency of HIV-specific memory CTLp is maintained in peripheral blood for years, but in advancing HIV disease the HIV-specific CTL response is impaired (18).
To determine the contribution of CD28-CD8+ T cells to Ag-specific CTL memory, in asymptomatic carriers of HCMV and HIV we generated multiple independent CTL clones specific for defined peptides of HCMV and HIV and used the hypervariable TCR ß-chain sequence of each immunodominant CTL clone to design a complementary oligonucleotide as a highly specific clonotypic probe. Using these probes we found large clone sizes of individual CTL clonotypes in the CD28- subpopulation of peripheral blood CD8+ T cells. We complemented these molecular studies by demonstrating high frequencies of functional virus-specific memory CTLp within the CD28- subpopulation using limiting dilution analysis (LDA).
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Two healthy HIV-seronegative laboratory donors and three asymptomatic HIV-infected subjects attending Addenbrooke’s Hospital (Cambridge, U.K.) were studied. All donors were HCMV seropositive, as determined by an IgG ELISA (Captia HCMV IgG immunoassay, Centocor, Malvern, PA). MHC class I tissue types were determined by serological typing (Lymphotype ABC-120, Biotest, Dreieich, Germany). The tissue types, CD4+ T cell counts, and plasma HIV RNA loads of the HIV-infected subjects were: H0009 (A2 A24 B62 B27), CD4 count 400/µl, viral load 3,000 copies/ml, no antiretroviral treatment; H0018 (A2 A3 B7 B44), CD4 count 390/µl, viral load 1,700 copies/ml, no antiretroviral treatment; and H0045 (A11 A29 B8 B44), CD4 count 250/µl, viral load 10,000/ml, started antiretroviral treatment 07/97 after which viral load was <50 copies/ml. The tissue types of the healthy HCMV carriers were: 005, A31 A33 B44 B35; and 011, A2 A23 B62 B44.
Viruses and cell lines
The recombinant vaccinia viruses used were vac pp65, vac gag, vac env, and vac T7 as a negative control as previously described (13, 18). Lymphoblastoid B cell lines (LCL) were generated from PBMC by EBV transformation (18).
Synthetic peptides
HCMV pp65 peptides were 17a (VFPTKDVAL, HLA-B35), 53 (DDVWTSGSDSDEELV, HLA-B35), 56 (TPRVTGGGAM, HLA-B7), 69 (NLVPMVATV, HLA-A2), and 72 (EFFWDANDIY, B12 (44)) (13). HIV env gp120 peptides were 740.18 (TQACPKVSFEPIPIHYCAPA), 740.19 (PIPIHYCAPAGFAILKCNNK, HLA-A2), and 7035.1 (AAEQLWVTVYYGVPVWKEAT, HLA-A11). HIV Gag peptides were 703.3 (LRPG GKKKYKLKHIV, HLA-A3) and 728 (KWILGLNKIVRMY, HLA-B27). The Medical Research Council AIDS Reagent Project, U.K., provided all HIV peptides.
Preparation of defined subsets of CD8+ cells for LDA and oligonucleotide probing
PBMC were prepared from fresh heparinized venous blood samples by Ficoll-Hypaque (Lymphoprep, Nyegaard, Oslo, Norway) density gradient centrifugation. CD16+ NK cells were depleted using anti-CD16 IgM (Leu 11b; Becton Dickinson, Oxford, U.K.) and complement (13). For healthy laboratory donors, CD4+ cells were also depleted using anti-CD4-conjugated MACS microbeads according to the manufacturer’s instructions (Miltenyi Biotech, Dreiech, Germany); enrichment for CD8+ cells gave improved sensitivity for clonotype detection. An aliquot of CD16- (CD4-) cells was further depleted of CD28+ cells using FITC-conjugated anti-CD28 (Coulter, Luton, U.K.) and anti-FITC MACS microbeads.
Negatively selected cells were washed once in PBS and resuspended in RPMI 1640 supplemented with 10% human HCMV-seronegative AB serum (Blood Transfusion Service, Addenbrookes Hospital), 10% FCS (Myoclone, Life Technologies, Paisley, U.K.), 2 mM L-glutamine, 105 IU of penicillin/l, and 100 mg of streptomycin/l (referred to as RPMI-HuAB). Aliquots of these cells were used as responder cells in LDA (see below), for RNA extraction, and for flow cytometry.
mAbs and surface phenotyping
Vß-chain usage was determined by three-color
immunofluorescence using a panel of TCR-specific FITC-conjugated mAbs
(the panel included Vß 1, 2, 3, 5.1, 5.2, 6.7, 7, 8.1, 11, 12, 13.6,
14, 16, 17, 19, 20, 21.3, 22 (Coulter); and Vß 13.1/13.3 and V2
(Serotec, Columbus, OH)) with PE-conjugated anti-CD8 and peridinin
chlorophyll protein (PerCP)-conjugated CD3 (Becton Dickinson). Other
antibodies used were FITC-conjugated anti-CD28 (Coulter) and
anti-CD4 (Becton Dickinson). The proportion of Vß+
cells was determined by staining aliquots of cells with the relevant
Vß-specific mAb, PE-conjugated anti-CD28 and PerCP-conjugated
anti-CD8 (Becton Dickinson). The purity of the CD28-depleted
lymphocyte populations was high (median, 98.5%; range, 89.4–99.8%;
n = 21).
Generation of virus-specific CTL in LDA
The methodology of LDA used has previously been described in detail (18). Replicate microcultures (n = 18–27) of responder cells were set up over an appropriate range of dilutions. APCs were autologous irradiated peptide-pulsed PBMC in RPMI-HuAB medium supplemented with human rIL-2 (Medical Research Council AIDS Reagent Project; final concentration, 5 IU/ml). On day 14, the cells in each individual well were divided into five aliquots that were assayed for cytotoxicity against different radiolabeled target cells in 4-h 51Cr release cytotoxicity assays. Target cells comprised autologous or MHC-mismatched LCL that had been infected for 18 h with vac pp65, vac gag, vac env, or vac T7 (multiplicity of infection = 10) and radiolabeled with 51Cr (Amersham, Aylesbury, U.K.) for 45 min at 37°C. Peptide-pulsed target cells were prepared by first labeling LCL with 51Cr and then pulsing with 50 µl of peptide (40 µg/ml) for a further 30 min. Target cells were washed three times and counted. The method of analysis has been described previously (13, 18).
Derivation of formal single-cell clones and expansion of clonally derived CTL microcultures
From selected LDA microcultures, formal single-cell clones were generated by subculture at 0.5 cells/well (14). Multiple independent clonally derived CTL cultures were generated by mitogen restimulation of residual cells from selected LDA microcultures at or below the dilution where <50% of replicate microcultures showed peptide-specific killing (14); at these low dilutions, individual LDA microcultures contained single peptide-specific clones (our own unpublished observations). mRNA was extracted, and cDNA was synthesized as previously described (14).
TCR ß-chain PCR amplification and sequencing
To determine TCR ß-chain V region usage of CTL lines or
clones, PCR amplification and sequencing were performed using a panel
of TCR Vß primers and a Cß primer as previously described (14). The
hypervariable CDR3 region was defined by Kabat et al., starting at
position 95 of Vß and finishing at the phenylalanine of the motif
FGXG within Jß (19). Sequence data presented in Table I
are available
from EMBL/GenBank/DDBJ under accession numbers AJ011545–AJ011556 and
AJ010895.
|
To quantify an individual peptide-specific CTL clone in PBMC, we
designed a complementary oligonucleotide probe 15–20 nucleotides long
based on the TCR ß-chain hypervariable NDN region and the ends of the
adjoining V and J regions. Such probes are highly specific for
individual CTL clonotypes, as reflected by very low binding of
individual clonotypic probes to amplified negative control cDNA (20)
(Fig. 1A). mRNA was extracted
from CD16-depleted or CD16- and CD28-depleted cells, reverse
transcribed into cDNA, and amplified in duplicate using a Vß-specific
primer (14) and a Cß-specific primer. A positive control sample from
the formal single cell CTL clone and a negative control sample from the
pooled PBMC of four HCMV- and HIV-seronegative donors was also
amplified at the same time in duplicate using the same primers. Forty
microliters of each PCR product was separated on a 1.3% agarose gel.
PCR products were transferred overnight to a Zeta-Probe nylon filter
(Bio-Rad, Hercules, CA) using standard techniques (21). Blotting buffer
was 0.6 M NaOH/0.2 M NaCl. The filter was washed in 2x SSC and baked
at 80°C for 30 min. It was then incubated in 15 ml of
prehybridization buffer (7% SDS and 0.25 M
Na2HPO4) for 1 h at 10–15°C below the
melting temperature of the clonotypic probe. Fifteen picomoles of
clonotypic probe was end labeled with [
-32P]dATP using
T4 polynucleotide kinase (Promega) as described by the manufacturer.
The probe was separated from unincorporated label using a Sephadex G-25
spin column (Amersham). Hybridization was conducted overnight at
10–15°C below the melting temperature of the clonotypic probe in
hybridization buffer (7% SDS, 0.25 M Na2HPO4,
and 10% polyethylene glycol 8000). The filter was washed for 15 min
three times in wash buffer (5% SDS and 20 mM
Na2HPO4). The amount of probe that had bound to
each sample on the filter was quantitated using an Instant Imager
(Beckman, Palo Alto, CA). The filter was exposed to x-ray film,
stripped by soaking in 0.4 M NaOH for 30 min, and washed in 2x SSC. It
was then rehybridized with a TCR ß-chain constant region probe
(AGATCTCTGCTTCTGATG) following the same protocol as that described
above. In each experiment it was possible to correct for differences in
radioactive labeling of the clonotypic and constant region probes by
measuring the radioactivity of each probe bound to the positive control
sample as a reference standard (TCR ß-chain sequences amplified from
the biologically derived CTL clone contain the unique hypervariable NDN
region and constant region in equal amounts). The proportion of
clonotype sequence within the total amplified TCR Vß sequence for a
given population of CD8+ cells was calculated as follows:
% of clonotype within Vß-expressing cells = 100 x ([cpm
clonotypic probe/cpm TCR constant probe for the T cell population of
interest]/[cpm clonotypic probe/cpm TCR constant probe for the
positive control clone]).
|
, the clone size per
106 CD8+ T cells was therefore: % of clonotype
sequence within all Vß13.6+ sequences x 1/(% of
Vß13.6+ cells that are CD8+) x % of
Vß13.6+CD8+ cells in total CD8+
cells x 106. |
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We identified five CTL epitopes in HIV env or gag and determined their MHC restriction (22). We identified five CTL epitopes restricted by four different HLA alleles from HCMV pp65 and determined their MHC restriction (13, 14).
The clonal composition of memory CTL specific for HIV gag and env epitopes is highly focused
To determine how many different TCR Vß gene segments were used by CTL specific to a given peptide, unstimulated PBMC and peptide-specific bulk CTL lines (obtained by pooling the residual cells from LDA microcultures that showed strong peptide-specific killing) were studied by two-color immunofluorescence using mAbs specific for defined Vß gene segments. In unstimulated PBMC of donor H0009, 2.6% of CD8+ T cells were Vß13.6+, and 3.6% were Vß22+. After stimulation with peptide 740.19, Vß13.6+ cells expanded to 84.6% of the CD8+ population; only 0.1% were Vß22+. After stimulation with peptide 728, 2.1% of responder CD8+ cells were Vß13.6+, and 29.8% were Vß22+.
We next analyzed the clonal composition of the peptide-specific CTL
response to identify how many different CTL clones contribute to the
peptide 740.19-specific Vß13.6+ CTL population. We
generated formal single cell clones and multiple independent, clonally
derived CTL cultures specific for HIV env and gag peptides, and
sequenced each TCR ß-chain (Table I).
In each of the three HIV-infected subjects studied, the clonal
composition of the memory CTL responses to gag and env peptides was
highly focused; for each donor, one predominant TCR ß-chain
nucleotide sequence was detected in multiple, independently derived
formal CTL clones and clonally derived CTL cultures specific for a
given peptide. In donor H0009, six of six independent peptide
740.19-specific CTL clones and clonal microcultures derived at two time
points had the same Vß13.6+ TCR ß-chain nucleotide
sequence, demonstrating that this CTL clone accounted for the large
majority of the peptide 740.19-specific memory CTLp in this donor. In
the same donor, gag peptide 728-specific CTL were also focused, since
both a CTL clone and the Vß22+ cells within a
peptide-specific bulk CTL line had the same ß-chain sequence. Only
30% of CD8+ lymphocytes within the peptide 728-specific
bulk CTL line were however Vß22+, indicating that other
clones expressing different Vß segments may be involved in the
recognition of this peptide. In donors H0018 and H0045, CTL
specific for three different HIV peptides were also highly focused.
These results closely resemble our previous observation of clonal
focusing of CTL specific for peptides of pp65 in healthy HCMV carriers
(14). In all donors in the current study we also identified the
clonotypes of immunodominant CTL specific for given pp65 peptides
(Table I) (14).
Large clone sizes of HIV and HCMV peptide-specific CTL clones in CD28-CD8+ cells demonstrated using clonotype-specific oligonucleotide probes
For each CTL clone, we designed a complementary oligonucleotide
based on the hypervariable region of the TCR ß-chain. To quantify
each clone within the CD16-depleted or CD16- and CD28-depleted cells,
cDNA was synthesized, amplified using the relevant Vß-specific
primer, and blotted onto a filter that was probed using the labeled
clonotypic probe. By stripping the filter and reprobing with a
conserved internal probe that detects all TCRs, the relative abundance
of clonotype sequence compared with the total sequence within that Vß
family could be calculated. From the relative abundance of clonotype
sequence within the Vß family, and the proportion of
Vß+ cells in the CD8+ population (determined
by flow cytometry), the clone size within the CD16-depleted or CD16-
and CD28-depleted T cell populations could be estimated (Fig. 1).
We found very large clone sizes of individual CTL clones specific for
pp65 peptides in both healthy HCMV carriers (Table II). A single CTL clone comprised up to
1.4% of all CD8+ T cells in PBMC. The size of
pp65-specific CTL clones generally remained stable over time.
HCMV-specific CTL clone sizes were similar or increased in
CD28-depleted CD8+ cells compared with those in nondepleted
cells. In donor 011, the size of Vß17+ pp65 peptide
69-specific CTL clone 11A was 1.5- to 3-fold greater in the
CD16-CD4-CD28- population than
in the CD16-CD4- population when examined at
four different time points (Table II). In donor 005, the size of
Vß20+ pp65 peptide 17/18-specific CTL clone 5A was also
generally greater in CD28- cells, in this case because of
an increased percentage of Vß20+ cells within the
CD28-CD8+ subpopulation; during the period of
study, 14–20% of all CD8+ cells were Vß20+,
whereas within the CD28-CD8+ subpopulation,
28–38% of cells were Vß20+.
|
). In donor H0018, we
identified three different pp65 peptide 56-specific CTL clonotypes,
each of which used Vß6.4. cDNA samples from different time points
were amplified using the Vß6.4-specific primer, and the PCR products
were analyzed with probes specific for each of three clonotypes (Fig. 2). The proportion of clonotype 18D
within Vß6.4-expressing cells was higher than that of clonotype 18C,
and both remained stable over time. The proportion of clonotype 18B
within Vß6.4-expressing cells decreased significantly between 01/98
and 04/98, but remained stable thereafter. Importantly, a very similar
decrease in the relative size of this clonotype was observed within the
CD28-depleted population analyzed in parallel (Fig. 2). Clonotypes 18C
and 18D act as internal controls for this decrease because they have
the same Vß segment as clonotype 18B. In the HIV-infected subjects,
for both HIV-specific and HCMV-specific CTL clonotypes the clone sizes
were similar or increased in the CD28-depleted populations compared
with those in undepleted cells (Table III).
|
|
We measured the frequency of memory CTLp specific for gag, env, and pp65 peptides in LDA, using as responder cells the CD16 (CD4-)-depleted PBMC or CD16 (CD4-)-CD28-depleted PBMC that were used for simultaneous clonotype probing (Tables II and III). The magnitude of MHC-restricted peptide-specific killing was very similar in individual microcultures derived from either CD16-depleted or CD16- and CD28-depleted responder cells (data not shown). We confirmed that CTL generated by stimulation with individual HIV or HCMV peptides could kill target cells infected with recombinant vaccinia viruses that expressed the relevant HCMV or HIV protein (data not shown) (22).
In healthy HCMV carriers, the frequencies of memory CTLp specific to
pp65 peptides were high and showed some variability over time (Table II). In donor 011, the frequencies of CTLp specific for pp65 peptide 69
and for pp65 peptide 72 were significantly higher in
CD16-CD4-CD28- cells than in
CD16-CD4- cells. In donor 005, the
frequencies of CTLp specific for pp65 peptide 17a and for pp65 peptide
53 were similar in both responder cell populations.
For all three HIV-infected subjects, the LDA frequencies of memory CTLp
specific for gag, env, and pp65 peptides were maintained at a stable
level over a period of up to 13 mo (Table III). We found that the
frequency of gag, env, or pp65 peptide-specific CTLp in the
CD28-depleted responder cells was generally similar to or higher than
the frequency of CTLp specific to the same peptide in the undepleted
population. In HIV-infected subject H0009,
CD16-CD28- cells also contained higher
frequencies of CTLp specific to pp65 peptide 69 and gag peptide 728
than CD16- cells. There were similar frequencies of
peptide-specific CTLp in both CD28-depleted and undepleted cells in
subjects H0018 and H0045.
Simultaneous comparison of clone size of defined CTL clonotypes and peptide-specific CTLp frequency
Tables II and III compare peptide-specific clone sizes and LDA
frequencies of peptide-specific CTLp at the same time point in the same
donor. The peptide-specific CTLp frequency measured in LDA reflects an
aggregate of the individual contributions of different CTL clonotypes
that are capable of responding to a given viral peptide in vitro. The
contributions of particular immunodominant clonotypes to the functional
response in vitro can be estimated from the proportion of responding
peptide-specific microcultures that contained the CTL clonotype. For
example, pp65 peptide 69-specific clonotype 9C from donor H0009 was
identified in four independent peptide-specific microcultures on 04/97;
similar observations were made for other clonotypes in other donors
(Table III). Because this clonotype accounts for a large proportion of
the total peptide 69-specific CTL response in this donor, we calculated
the ratio of functional CTLp frequency: clone size as an estimate of
the cloning efficiency of the specific CTL clonotype. In each cell
population, these two values are, in fact, very similar; on 20/5/98, in
the CD16- population, the size of clonotype 9C was 3800
clones/106 CD8+ T cells, and the frequency of
peptide-specific CTLp was 4300/106 CD8+ T cells
(Table III). Similarly, within the corresponding
CD16-CD28- subpopulation, the size of the
clonotype was 14,000 clones/106 CD8+ T cells,
which was comparable to the frequency of peptide 69-specific CTLp in
LDA, namely 12,000 CTLp/106 CD8+ T cells. Where
analyzed, for each donor the same immunodominant clone made up a
similar proportion of all the peptide-specific clones in both the
CD28-depleted and undepleted responder CD8+ cells (Tables
II and III).
Other CTL clones (e.g., subdominant clonotype 45B identified in one of
four peptide-specific Vß13.1+ microcultures; Table I),
whose sizes we have not quantified, also contribute to the functional
response observed in LDA. This is confirmed by the fact that in donor
H0009 the frequency of gag peptide 728-specific CTLp is consistently
greater than the clone size of 9B, and in donor H0045 the frequency of
pp65 peptide 72-specific CTLp is greater then the clone size of 45D
(Table III), resulting in a CTLp:clone size ratio in excess of 100%.
In general, the CTLp:clone size ratio was between 12–90%. In the case
of the highly focused peptide 740.19-specific CTL response of donor
H0009 (Table IA), the functional LDA frequency was substantially lower
than the clone size (CTLp:clone size ratio, <7%). It is possible that
this large clone genuinely had impaired function or that in vitro
culture was suboptimal, possibly because the sequence of the env
peptide 740.19 used to stimulate CTL in vitro may have differed from
the endogenous HIV viral sequence(s) in H0009 that stimulated this
clonal expansion in vivo.
Importantly, at each time point in each donor, the CTLp:clone size ratio of CD28-depleted cells was very similar to that of the undepleted CD8+ T cell population as a whole, indicating that the large virus-specific clones in the CD28- population maintain their ability to function in vitro. The only exception was donor H0018, in whom the CTLp:clone size ratio of gag peptide 703.3-specific CTL was reduced in the CD28- population compared with that in the undepleted population.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We previously found that the CTL response to four different HCMV pp65 peptides was highly focused; in general, the majority of CTL clones specific for a defined pp65 peptide from any one virus carrier used only one or two different TCR at the level of nucleotide sequence (14). Here we found a high degree of clonal focusing among memory CTL specific for a given HIV gag or env peptide/MHC complex within each of three HIV-infected subjects. Previous studies that have examined the clonal composition of the CTL response to other persistent human virus infections within individuals have observed a comparable degree of clonal focusing (23). In a single HIV-infected subject, multiple independent CTL clones specific for an HLA-B14-restricted env peptide derived at different time points over the course of 36 mo used the same TCR ß-chain (24). Similarly, multiple independent CTL clones specific to an HLA-B8-restricted EBV peptide derived from one virus carrier at one time point all used the same TCR (25). The CTL responses to different HTLV-1 peptides have also been observed to be oligoclonal within individual donors (26).
In healthy HCMV carriers we previously measured very high frequencies
of CTLp specific for individual pp65 peptides by LDA. Because the
peptide-specific CTL response is highly focused at the clonal level,
this indicated that the large population of circulating memory CTL
against a given HCMV peptide contains individual CTL clones that had
undergone extensive clonal expansion in vivo. Here, using the clonotype
probing technique, we have produced direct evidence confirming that
individual HIV- and HCMV-specific CTL clones can indeed be very large,
sufficient to permit reproducible quantitation of the size of
individual CTL clonotypes directly ex vivo independently of function.
In this study individual peptide-specific CTL clones generally
accounted for 2–66% of all CD8+ T cells that expressed
the same Vß segment as the clone; this corresponded to a clone size
of between 0.15–3.1% of all CD8+ T cells. The clonotyping
results also indicated that individual CTL clone sizes were maintained
at a relatively constant level over time. In a healthy HCMV carrier, we
found that the size of a Vß17+ pp65 peptide 69-specific
CTL clonotype was between 5,100–14,000 cells/106
CD8+ T cells when measured on four separate occasions over
a 15-mo period (Table II). The sizes of individual CTL clones derived
from other donors were also generally maintained with no more than a
4-fold change in clonal size over the period of observation. In an
HIV-infected subject, one CTL clonotype showed a 7-fold reduction in
size within Vß6.4+ cells, while the size of two other
Vß6.4+ clonotypes specific for the same peptide remained
stable (Fig. 2). Because both HIV and HCMV are persistent viruses
characterized by sustained or intermittent viral reactivation and Ag
expression, repeated exposure of virus-specific memory CTL to viral
Ag in vivo over time may lead to selective expansion and maintenance of
large memory CTL clones, possibly those that express certain high
affinity TCR (27).
By clonotype probing of CD28-depleted cell populations, we found large clone sizes of individual HIV-specific and HCMV-specific CTL clones in CD28- cells. The clone size of HIV- and HCMV-specific CTL clonotypes was similar or increased within the CD28- population compared with that in undepleted CD8+ cells in the HIV-infected subjects and in healthy HCMV carriers. In normal adult donors, oligoclonal expansions of unknown Ag specificity have previously been observed in CD8+ T cells and in particular within the CD28-CD8+ T cell subpopulation (28, 29, 30, 31, 32, 33, 34, 35, 36). Our demonstration of large memory CD8+ CTL clones that are specific for HCMV and HIV within the CD28-CD8+ subpopulation suggests that memory CTL specific for persistent viruses may account for many of these hitherto unexplained oligoclonal expansions.
In all three HIV-infected subjects, the LDA frequencies of functional
memory CTLp specific for gag, env, and pp65 peptides were maintained at
stable levels over a period of up to 13 mo. In healthy HCMV carriers,
the frequencies of memory CTLp specific to pp65 peptides were more
variable. As shown in Table II, in some instances the clone size of an
individual peptide-specific CTL clone was greater than the frequency of
CTLp specific to the same peptide, which indicates that not all the CTL
clones detected by the clonotype probing technique grew in LDA. It is
recognized that the functional response requiring clonal expansion in
vitro in LDA may underestimate the absolute number of Ag-specific cells
as determined by peptide/MHC class I tetramer staining (37). Tetramer
staining detects the aggregate of Ag-specific cells, but does not
distinguish between individual CTL clonotypes. In this study we used
clonotype probing rather than tetramer staining not only because we
wished to study memory CTL responses specific for seven viral peptides
restricted by five different MHC alleles, but also because the
clonotype probing technique provides a higher level of resolution by
allowing the study of the sizes of individual peptide-specific CTL
clones over time and the segregation of individual clones into
different phenotypic subpopulations.
Other observers have suggested that CD28-CD8+ cells as a population have impaired proliferative responses to in vitro mitogenic stimulation with PHA, anti-CD2, or anti-CD3 mAbs or a combination of the above (2, 3, 5, 6, 29, 33). In contrast, Gomez et al. observed significant proliferation of the CD28-CD8+ population in anti-EBV and anti-influenza T cell lines generated from PBMC of subjects responding to these viruses (38). Strong proliferation of CD28-CD8+ cells from HIV-infected subjects was also observed after in vitro restimulation with autologous blast cells that may have expressed HIV Ag (39). The proliferation of CD28-CD8+ T cells may therefore differ depending upon the conditions of stimulation in vitro. It is possible that CD28-CD8+ cells may be particularly susceptible to apoptosis upon stimulation with mitogen (5, 40). In our experiments upon stimulation with autologous irradiated PBMC pulsed with specific peptide, single CD28- Ag-specific memory CTLp were capable of undergoing at least 12–14 divisions necessary for detection of short term CTL clones in LDA. The frequency of gag, env, or pp65 peptide-specific CTLp within the CD28-depleted responder cells was similar to or higher than the frequency of CTLp specific for the same peptide in the undepleted responder cell population. From CD28-depleted responder cells we derived functional CTL clones possessing the same TCR ß-chain sequence as clones derived from undepleted responder cells (data not shown), confirming that the large virus-specific T cell clones within the CD28- population also comprised functional cells. In four of the five donors, the estimated cloning efficiency (the LDA response as a proportion of peptide-specific CTL clone size) in the CD28-depleted population was similar to that in the undepleted population (Tables II and III). This indicates that the in vitro function of virus-specific CD28-CD8+ CTLp was comparable to that of the CD8+ T cell population as a whole. It is possible that these CD28-CD8+ CTLp may express other molecules that are capable of providing costimulation in the absence of CD28, as appears to be the case in CD28 knockout mice (41). Therefore, at least during the asymptomatic phase of HIV infection, many virus-specific CD28-CD8+ CTLp were able to function in vitro, arguing against the suggestion that these cells are terminally differentiated (5). However, it is possible that during the course of advancing HIV disease, the function of virus-specific CD28- memory CTL clones may decline, and we are addressing this question in longitudinal studies.
In conclusion, by molecular analysis we found large clone sizes of individual virus-specific CTL clonotypes in CD28-CD8+ T cells of subjects asymptomatically infected with HIV and/or HCMV, and by functional assay we demonstrated that rather than being terminally differentiated, CD28-CD8+ cells contain high frequencies of functional virus-specific memory CTL clones.
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. A. J. Carmichael, Department of Medicine, University of Cambridge Clinical School, Hills Road, Cambridge, UK CB2 2QQ. E-mail address:
3 Abbreviations used in this paper: HCMV, human CMV; CTLp, CTL precursor; LDA, limiting dilution analysis; PerCP, peridinin chlorophyll protein.
Received for publication January 19, 1999. Accepted for publication April 1, 1999.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  L. Yin, Z. C. Kou, C. Rodriguez, W. Hou, M. M. Goodenow, and J. W. Sleasman Antiretroviral Therapy Restores Diversity in the T-Cell Receptor V{beta} Repertoire of CD4 T-Cell Subpopulations among Human Immunodeficiency Virus Type 1-Infected Children and Adolescents Clin. Vaccine Immunol., September 1, 2009; 16(9): 1293 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Heffner and D. T. Fearon Loss of T cell receptor-induced Bmi-1 in the KLRG1+ senescent CD8+ T lymphocyte PNAS, August 14, 2007; 104(33): 13414 - 13419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. C. Miles, M. van der Sande, D. Jeffries, S. Kaye, J. Ismaili, O. Ojuola, M. Sanneh, E. S. Touray, P. Waight, S. Rowland-Jones, et al. Cytomegalovirus Infection in Gambian Infants Leads to Profound CD8 T-Cell Differentiation J. Virol., June 1, 2007; 81(11): 5766 - 5776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Akbar and M. Vukmanovic-Stejic Telomerase in T Lymphocytes: Use It and Lose It? J. Immunol., June 1, 2007; 178(11): 6689 - 6694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kobayashi, T. Kondo, H. Takata, S. Yokota, and M. Takiguchi Functional and phenotypic analysis of human memory CD8+ T cells expressing CXCR3. J. Leukoc. Biol., August 1, 2006; 80(2): 320 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Baeten, S. Louis, C. Braud, C. Braudeau, C. Ballet, F. Moizant, A. Pallier, M. Giral, S. Brouard, and J.-P. Soulillou Phenotypically and Functionally Distinct CD8+ Lymphocyte Populations in Long-Term Drug-Free Tolerance and Chronic Rejection in Human Kidney Graft Recipients J. Am. Soc. Nephrol., January 1, 2006; 17(1): 294 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vidric, W.-K. Suh, U. Dianzani, T. W. Mak, and T. H. Watts Cooperation between 4-1BB and ICOS in the Immune Response to Influenza Virus Revealed by Studies of CD28/ICOS-Deficient Mice J. Immunol., December 1, 2005; 175(11): 7288 - 7296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wikby, F. Ferguson, R. Forsey, J. Thompson, J. Strindhall, S. Lofgren, B.-O. Nilsson, J. Ernerudh, G. Pawelec, and B. Johansson An Immune Risk Phenotype, Cognitive Impairment, and Survival in Very Late Life: Impact of Allostatic Load in Swedish Octogenarian and Nonagenarian Humans J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2005; 60(5): 556 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Weekes, M. R. Wills, J. G. P. Sissons, and A. J. Carmichael Long-Term Stable Expanded Human CD4+ T Cell Clones Specific for Human Cytomegalovirus Are Distributed in Both CD45RAhigh and CD45ROhigh Populations J. Immunol., November 1, 2004; 173(9): 5843 - 5851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ahmad and F. Alvarez Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis J. Leukoc. Biol., October 1, 2004; 76(4): 743 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Gold, M. W. Munks, M. Wagner, C. W. McMahon, A. Kelly, D. G. Kavanagh, M. K. Slifka, U. H. Koszinowski, D. H. Raulet, and A. B. Hill Murine Cytomegalovirus Interference with Antigen Presentation Has Little Effect on the Size or the Effector Memory Phenotype of the CD8 T Cell Response J. Immunol., June 1, 2004; 172(11): 6944 - 6953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Karrer, M. Wagner, S. Sierro, A. Oxenius, H. Hengel, T. Dumrese, S. Freigang, U. H. Koszinowski, R. E. Phillips, and P. Klenerman Expansion of Protective CD8+ T-Cell Responses Driven by Recombinant Cytomegaloviruses J. Virol., March 1, 2004; 78(5): 2255 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Gandhi, M. R. Wills, G. Okecha, E. K. Day, R. Hicks, R. E. Marcus, J. G. P. Sissons, and A. J. Carmichael Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation Blood, November 1, 2003; 102(9): 3427 - 3438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Aandahl, J. K. Sandberg, K. P. Beckerman, K. Tasken, W. J. Moretto, and D. F. Nixon CD7 Is a Differentiation Marker That Identifies Multiple CD8 T Cell Effector Subsets J. Immunol., March 1, 2003; 170(5): 2349 - 2355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Karrer, S. Sierro, M. Wagner, A. Oxenius, H. Hengel, U. H. Koszinowski, R. E. Phillips, and P. Klenerman Memory Inflation: Continuous Accumulation of Antiviral CD8+ T Cells Over Time J. Immunol., February 15, 2003; 170(4): 2022 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kondo, M. S. Topp, H.-P. Kiem, Y. Obata, Y. Morishima, K. Kuzushima, M. Tanimoto, M. Harada, T. Takahashi, and Y. Akatsuka Efficient Generation of Antigen-Specific Cytotoxic T Cells Using Retrovirally Transduced CD40-Activated B Cells J. Immunol., August 15, 2002; 169(4): 2164 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Wills, G. Okecha, M. P. Weekes, M. K. Gandhi, P. J. G. Sissons, and A. J. Carmichael Identification of Naive or Antigen-Experienced Human CD8+ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cell Response J. Immunol., June 1, 2002; 168(11): 5455 - 5464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tomiyama, T. Matsuda, and M. Takiguchi Differentiation of Human CD8+ T Cells from a Memory to Memory/Effector Phenotype J. Immunol., June 1, 2002; 168(11): 5538 - 5550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Holznagel, S. Norley, S. Holzammer, C. Coulibaly, and R. Kurth Immunological changes in simian immunodeficiency virus (SIVagm)-infected African green monkeys (AGM): expanded cytotoxic T lymphocyte, natural killer and B cell subsets in the natural host of SIVagm J. Gen. Virol., March 1, 2002; 83(3): 631 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Pitcher, S. I. Hagen, J. M. Walker, R. Lum, B. L. Mitchell, V. C. Maino, M. K. Axthelm, and L. J. Picker Development and Homeostasis of T Cell Memory in Rhesus Macaque J. Immunol., January 1, 2002; 168(1): 29 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nishio, M. Suzuki, N. Miyasaka, and H. Kohsaka Clonal Biases of Peripheral CD8 T Cell Repertoire Directly Reflect Local Inflammation in Polymyositis J. Immunol., October 1, 2001; 167(7): 4051 - 4058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Hislop, N. H. Gudgeon, M. F. C. Callan, C. Fazou, H. Hasegawa, M. Salmon, and A. B. Rickinson EBV-Specific CD8+ T Cell Memory: Relationships Between Epitope Specificity, Cell Phenotype, and Immediate Effector Function J. Immunol., August 15, 2001; 167(4): 2019 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fiorentini, S. Licenziati, G. Alessandri, F. Castelli, S. Caligaris, M. Bonafede, M. Grassi, E. Garrafa, A. Balsari, A. Turano, et al. CD11b Expression Identifies CD8+CD28+ T Lymphocytes with Phenotype and Function of Both Naive/Memory and Effector Cells J. Immunol., January 15, 2001; 166(2): 900 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kaur, C. L. Hale, S. Ramanujan, R. K. Jain, and R. P. Johnson Differential Dynamics of CD4+ and CD8+ T-Lymphocyte Proliferation and Activation in Acute Simian Immunodeficiency Virus Infection J. Virol., September 15, 2000; 74(18): 8413 - 8424. [Abstract] [Full Text]
|
|
|
|
|
|
G. M. A. Gillespie, M. R. Wills, V. Appay, C. O'Callaghan, M. Murphy, N. Smith, P. Sissons, S. Rowland-Jones, J. I. Bell, and P. A. H. Moss Functional Heterogeneity and High Frequencies of Cytomegalovirus-Specific CD8+ T Lymphocytes in Healthy Seropositive Donors J. Virol., September 1, 2000; 74(17): 8140 - 8150. [Abstract] [Full Text]
|
|
|
|
|
|
L. A. Trimble, P. Shankar, M. Patterson, J. P. Daily, and J. Lieberman Human Immunodeficiency Virus-Specific Circulating CD8 T Lymphocytes Have Down-Modulated CD3zeta and CD28, Key Signaling Molecules for T-Cell Activation J. Virol., August 15, 2000; 74(16): 7320 - 7330. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. Zaia, J.G. P. Sissons, S. Riddell, D. J. Diamond, M.R. Wills, A.J. Carmichael, M.P. Weekes, M. Gandhi, C. La Rosa, M. Villacres, et al. Status of Cytomegalovirus Prevention and Treatment in 2000 Hematology, January 1, 2000; 2000(1): 339 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Coulie, V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard, and T. Boon A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 PNAS, August 28, 2001; 98(18): 10290 - 10295. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
